Anti-inflammatory Drug May Shorten Covid-19 Recovery Time - COVID-19 Clinical Trial
Breaking News | COVID-19

Anti-inflammatory Drug May Shorten Covid-19 Recovery Time

A drug company says that adding an anti-inflammatory medicine to a drug already widely used for hospitalized Covid-19 patients shortens their time to recovery by an additional day.Eli Lilly announced the results Monday from a 1,000-person study sponsored by the U.S. National Institute of Allergy and Infectious Diseases. The result have not yet been published or reviewed by independent scientists, but the government confirmed that Lilly’s statement was accurate.

The study tested baricitinib, a pill that Indianapolis-based Lilly already sells as Olumiant to treat rheumatoid arthritis, the less common form of arthritis that occurs when a mistaken or overreacting immune system attacks joints, causing inflammation. An overactive immune system also can lead to serious problems in coronavirus patients.


Lonza Works With Humanigen on COVID-19 Drug Candidate Lenzilumab

Swiss contract drug maker Lonza struck a deal with California-based biopharmaceutical company Humanigen to expand manufacturing capacity for Humanigen’s lenzilumab, a drug candidate in late-stage clinical trials for COVID-19.Lenzilumab is in phase III clinical trials to determine whether the drug can prevent and treat an immune hyper-response in COVID-19 patients called “cytokine storm”, the companies said in a statement on Tuesday.

The collaboration with Lonza will provide Humanigen with additional production capacity for lenzilumab at Lonza’s facilities at Hayward, California, with operations intended to start in 2021, the companies said.Lonza is also working with Moderna to make its COVID-19 vaccine candidate and with China’s Junshi Biosciences to help produce a neutralizing antibody against COVID-19.

Share this:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on reddit
Reddit
Share on email
Email
Scroll to Top

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.

Want to stay informed?

With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.